Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 26 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal · 3% above its 52-week low
| 4.34 | 52-week high | +226.32% |
| 1.97 | Previous month high | +48.35% |
| 1.77 | Previous week high | +33.08% |
| 1.61 | Previous week low | +21.05% |
| 1.60 | Previous month low | +20.30% |
| 1.49 | R3 (classic) | +12.03% |
| 1.45 | R2 (classic) | +9.02% |
| 1.41 | Previous day high | +6.02% |
| 1.39 | R1 (classic) | +4.51% |
| 1.35 | Pivot | +1.50% |
| 1.33 | Price now | |
| 1.31 | Previous day low | −1.50% |
| 1.29 | 52-week low | −2.63% |
| 1.29 | S1 (classic) | −3.01% |
| 1.25 | S2 (classic) | −6.02% |
| 1.19 | S3 (classic) | −10.53% |
None of the 29 investors followed here reported a position in GANX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GANX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -44.1 | 45.0 | -25.7 | -2.6 | 3.2 | 4.1 | -17.2 | 7.1 | -3.9 | -23.1 | −58.7% | ||
| 2025 | -1.4 | 0.0 | -10.3 | 7.3 | -13.7 | 1.7 | -18.9 | 36.3 | -11.1 | 10.7 | 78.6 | -8.0 | +49.1% |
| 2024 | 18.5 | 16.0 | -16.0 | -22.3 | -13.0 | -49.8 | -15.6 | 0.9 | 63.3 | 40.4 | -25.6 | 16.1 | −33.8% |
| 2023 | 26.2 | 5.3 | 15.9 | 4.4 | -8.3 | -2.8 | -11.4 | -16.6 | -0.9 | -12.8 | -25.2 | 52.6 | +4.3% |
| 2022 | -26.3 | -7.7 | 10.8 | -16.4 | -12.9 | 20.8 | 10.6 | -13.3 | -5.5 | 2.5 | -9.0 | 3.0 | −42.4% |
| 2021 | -19.0 | -12.3 | -5.6 | -20.0 | -2.5 | -4.6 | -6.5 | 4.0 | -25.0 | −63.6% |
No insider transactions reported for GANX.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Buy / hold / sell counts